What Is Ipamorelin? The Selective GH Secretagogue Explained

Reviewed by Thomas Okafor, Peptide Chemist · Updated October 2026

Ipamorelin is a synthetic five-amino-acid peptide that mimics ghrelin, the “hunger hormone,” to signal the pituitary gland to release a short pulse of the body’s own growth hormone. It’s studied mainly for growth hormone release and, in one drug program, for restarting gut movement after surgery.

Ipamorelin has more human data than most research peptides: a 1999 study in healthy men measured how it behaves in the body, and a company later tested it in surgery patients. That trial didn’t meet its goals, and ipamorelin was never approved. Much of what people say about muscle, fat loss and sleep comes from animal work or from growth hormone research in general.

Ipamorelin is sold for research use only. This guide is educational and isn’t medical advice; see our Medical Disclaimer.

What Is Ipamorelin?

Ipamorelin is a lab-made peptide created by Novo Nordisk scientists in Denmark in the late 1990s. The team was hunting for a growth hormone releaser that did one job cleanly, and in 1998 they published it as “the first selective growth hormone secretagogue,” meaning it raised growth hormone without dragging other stress hormones up with it.

A secretagogue is anything that makes a gland secrete something. Ipamorelin belongs to a family of compounds called growth hormone secretagogues (GHS), which also includes older growth hormone-releasing peptides (GHRPs) like GHRP-2 and GHRP-6, and the oral compound ibutamoren (MK-677).

The chemistry. Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Three of its five building blocks aren’t found in normal human proteins: Aib (a modified alanine) and two “D” amino acids, which are mirror-image versions of the usual ones. Chemists use these swaps because the body’s enzymes struggle to chop them up, so the peptide lasts longer than a natural chain would. It weighs about 712 daltons (formula C38H49N9O5), tiny next to growth hormone itself.

There’s a nice twist in the timeline. Scientists found the receptor ipamorelin targets before they knew what it was for. In 1996, a Merck team identified a pituitary receptor that responded to synthetic growth hormone releasers, but the body’s own key for that lock was unknown. Three years later, Japanese researchers discovered ghrelin, a hormone made in the stomach, as its natural partner. So ipamorelin was designed to fit a lock whose real key hadn’t been found yet.

The history. In Novo Nordisk’s 1998 paper, Raun and colleagues showed ipamorelin released growth hormone in rat cells, anesthetized rats and pigs, with a strength similar to GHRP-6. A 1999 study in healthy men followed. The rights later went to Helsinn Therapeutics, which tested an intravenous version for postoperative ileus, the stalled bowel that often follows abdominal surgery. After the trial results in 2014, no company has published further drug development.

Also known as: ipamorelin, NNC 26-0161 and “CJC/Ipa”

In early papers, ipamorelin appears under its Novo Nordisk code, NNC 26-0161. Research vials are usually labeled ipamorelin acetate, the salt form. Online, you’ll also see “CJC/Ipa” or “CJC-1295/Ipamorelin,” which refers to a combination with a different peptide, CJC-1295. That pairing has its own breakdown in our CJC-1295 vs Ipamorelin comparison.

How Does Ipamorelin Work?

Ipamorelin mimics ghrelin and binds the GHS-R1a receptor on growth hormone-making cells in the pituitary, triggering a pulse of the body’s own growth hormone. The pulse peaks within about an hour and then fades. The liver then answers growth hormone by making IGF-1, the hormone behind many of growth hormone’s effects.

It helps to know that your pituitary has two main “doors” for releasing growth hormone. One is the GHRH receptor, which answers growth hormone-releasing hormone from the brain. The other is the ghrelin receptor, which answers ghrelin, a hormone your stomach makes when it’s empty. Ipamorelin knocks on the ghrelin door. Compounds like sermorelin, CJC-1295 and tesamorelin knock on the GHRH door. When both are pressed at once, the release is larger, which is why the two types are often discussed together.

Here’s what’s known about each step, and where that knowledge comes from:

• Ghrelin receptor binding (lab): in rat pituitary cells, ipamorelin released growth hormone about as strongly as GHRP-6, and blocking the GHRP receptor stopped the effect.
• Growth hormone pulse (human): in healthy men, a 15-minute infusion produced one burst of growth hormone that peaked at about 40 minutes and dropped back to baseline. The peptide’s own half-life was about 2 hours.
• Selectivity (animal): in pigs, ipamorelin didn’t raise ACTH or cortisol, even at doses more than 200 times what was needed for growth hormone release. GHRP-2 and GHRP-6 did raise both.
• No effect on other pituitary hormones (animal): the same pig studies found no change in FSH, LH, prolactin or thyroid-stimulating hormone.
• Downstream IGF-1 (animal, mixed): in a 15-day rat study, total IGF-1 levels didn’t change, even though bone growth sped up.

What does ipamorelin do, then? In short, it causes a brief growth hormone release. Its “cleanest” reputation, with no cortisol spike, comes mainly from animal work. The 1999 human study measured growth hormone, not stress hormones, so that selectivity hasn’t been carefully confirmed in people.

One thing worth keeping in mind: because ipamorelin uses the ghrelin receptor, it touches the same system that drives hunger. That’s relevant to the fat-loss claims covered below.

What Is Ipamorelin Used For in Research?

Ipamorelin has been studied for growth hormone release (human), gut motility after surgery (human and animal), bone growth and strength (animal), and body composition (animal). Only the first two have human data, and the surgery trial didn’t show a clear benefit. Claims about muscle, sleep and fat loss go beyond what’s been tested.

Growth hormone release

What was studied: the 1999 Pharmaceutical Research trial gave five rising infusion rates to healthy male volunteers, eight per dose level, and measured blood levels of ipamorelin and growth hormone.

What it found: every dose produced a single growth hormone pulse, and the response grew with the dose. The body cleared ipamorelin with a half-life of about 2 hours.

What it doesn’t show: this was a one-time infusion. It says nothing about repeated use, long-term IGF-1 levels, or any change in muscle, fat or health.

Gut motility after surgery

What was studied: ghrelin speeds up the gut, so Helsinn tested ipamorelin for postoperative ileus. Rat studies first showed it sped up stomach emptying and gut transit after abdominal surgery. Then came a Phase 2 randomized trial in 117 bowel-resection patients, who got intravenous ipamorelin or placebo for up to seven days.

What it found: patients on ipamorelin tolerated a solid meal a median of 25.3 hours after the first dose, against 32.6 hours on placebo. That gap was small enough to be chance (p = 0.15), and no secondary measure separated the groups either.

What it doesn’t show: proof that it works for ileus. It was well tolerated in this setting, but a trend isn’t a result.

Bone growth and strength

What was studied: several Novo Nordisk and university rat studies looked at bone.

What it found: ipamorelin sped up leg-bone growth in rats over 15 days, from 42 to as much as 52 micrometers a day. Over 12 weeks, it increased bone mineral content in adult female rats. Another study found it offset the loss of muscle strength and bone formation caused by steroid drugs in rats.

What it doesn’t show: any effect on human bones or muscles. No human study has measured either.

Body composition

What was studied: Cambridge researchers compared ipamorelin with growth hormone in normal mice and in mice that can’t make growth hormone.

What it found: the opposite of the online claims. Ipamorelin increased body fat relative to body weight, raised the appetite-linked hormone leptin, and increased food intake. Growth hormone itself either reduced fat or had no effect.

What it doesn’t show: what happens in people. Mice aren’t small humans, but this is the most direct body-fat study there is.

What ipamorelin hasn’t been shown to do

Ipamorelin hasn’t been shown to build muscle, burn belly fat, improve sleep, slow aging or speed injury recovery in people. Those claims borrow from what growth hormone does in general, or from forum stories. Growth hormone does peak during deep sleep, but no study has tested whether ipamorelin changes sleep.

What Does the Human Research Show?

The human research on ipamorelin is thin. It covers one study measuring how the body processes it in healthy men, one published Phase 2 trial in surgery patients that missed its goals, and a second, larger Phase 2 trial whose results were never posted. No human study has tested it for muscle, fat loss, sleep or aging.

PubMed and ClinicalTrials.gov searched October 5, 2026 (54 PubMed records for “ipamorelin”).

Why was ipamorelin development stopped? No company press release explains it. The record shows what happened: the published Phase 2 trial found no clear benefit, the larger follow-up trial ended in 2014 without posting results, and no sponsor has registered a new ipamorelin trial since. That pattern usually means a program has been shelved.

There’s also a gap worth naming. Most of what clinics describe, such as weekly routines, months of use and changes in body composition, has never been studied in a trial. The 1999 data describe a single dose in a lab; people online describe months of use. Our Editorial Policy explains how we label these evidence levels.

What would it take to answer the questions people actually ask? A trial would need to give ipamorelin, or a placebo, to adults for months, track IGF-1, blood sugar and body composition with scans, and follow people long enough to catch slower problems. Think of the difference between test-driving a car around the block and owning it for five years. The 1999 study was the drive around the block. Nobody has done the five years.

Ipamorelin Side Effects and Safety

In the surgery trial, side effects with ipamorelin were about as common as with placebo, which says little in a hospital setting where almost everyone had some symptom. Long-term effects are unknown. Expected risks come from raising growth hormone and from the quality of research-grade vials.

Reported in human studies: in the Phase 2 trial, 87.5% of the ipamorelin group and 94.8% of the placebo group had at least one adverse event after surgery, with no new safety pattern reported. The FDA’s safety review notes that a published study reported serious adverse events, including a death, when ipamorelin was given intravenously for gut motility. The FDA also flags a risk of immune reactions from clumping or impurities.

Expected from the mechanism: raising growth hormone and IGF-1 can cause water retention, joint aches, numbness or tingling in the hands, and higher blood sugar. Because ipamorelin acts on the ghrelin system, increased hunger is also plausible, as seen in the mouse study above. These come from growth hormone research in general, not ipamorelin trials.

Anecdotal only: users online report headaches, flushing, lightheadedness, injection-site redness, hunger and vivid dreams. None of these have been measured in a controlled study.

Product quality: research-grade vials aren’t made to drug standards, and the FDA notes ipamorelin’s unusual amino acids make it harder to characterize. Wrong amounts, impurities and bacterial toxins are real risks. Our peptide COA guide explains what a lab report should show.

Who should avoid ipamorelin

People with active cancer or a cancer history face the biggest open question, since growth hormone and IGF-1 promote cell growth. Others with extra reasons to stay away include anyone pregnant or breastfeeding, people with diabetes or prediabetes (growth hormone raises blood sugar), people under 18, anyone with pituitary disease, and athletes in drug-tested sport.

Does ipamorelin raise cortisol?

Not in the animal studies. In pigs, ipamorelin didn’t raise cortisol or ACTH even at very high doses, which is what set it apart from GHRP-2 and GHRP-6. That’s the main reason it’s called “selective.” Human data on cortisol are limited, so “doesn’t raise cortisol” is best read as “didn’t in animals.”

Ipamorelin vs Tesamorelin

Ipamorelin and tesamorelin both raise growth hormone, through different doors. Ipamorelin works through the ghrelin receptor and was never approved. Tesamorelin works through the GHRH receptor and is FDA-approved (as Egrifta) to reduce belly fat in adults with HIV-related lipodystrophy.

The same comparison comes up with sermorelin, another GHRH-door compound, which our sermorelin vs ipamorelin page covers. For the most common pairing online, see CJC-1295 vs Ipamorelin, and our tesamorelin guide covers that drug’s trials in full.

Is Ipamorelin Legal? Why Is It Banned in Sports?

Ipamorelin isn’t FDA-approved for any use, and it’s sold in the US as a “research use only” chemical. The FDA has flagged it as a compounding safety risk, and the World Anti-Doping Agency bans it in sport at all times. That combination is why you’ll see it described as both “legal to buy” and “banned.”

FDA status. On September 29, 2023, the FDA placed ipamorelin acetate in Category 2, its list of bulk substances that may pose serious safety risks in compounding. The FDA cited immune-reaction risk from impurities and the serious adverse events in the intravenous study. On the 503A side, which covers regular compounding pharmacies, the nomination for ipamorelin was later withdrawn by the people who submitted it, so it’s no longer listed in any 503A category. On the 503B side, which covers larger outsourcing facilities, it remains in Category 2. Either way, ipamorelin isn’t on the approved list of substances pharmacies may use. It also wasn’t part of the July 2026 FDA advisory meeting that reviewed BPC-157, TB-500, KPV and others.

Research use only. Research-grade ipamorelin is sold labeled “not for human consumption.” That label is what allows sale for lab work, and it means no one checks these vials the way medicines are checked. Clinics that offer ipamorelin are operating in a legal gray area. Our guide to whether research peptides are legal covers the wider rules.

Sport. The 2026 WADA Prohibited List names ipamorelin under class S2.2.4, growth hormone secretagogues, prohibited in and out of competition. Anti-doping labs have published urine tests that detect it, so a positive test is a real possibility.

FDA and WADA status checked October 5, 2026.

Where Ipamorelin Fits: Needs & Symptoms

Ipamorelin shows up in two research areas: sleep and energy, because growth hormone release peaks during deep sleep, and muscle and performance, because growth hormone affects body composition. In both cases, the link is about growth hormone in general; ipamorelin itself hasn’t been tested for sleep or muscle in people. The cards on those pages describe it as a research compound, and this guide is where each claim gets its evidence label.

• Sleep & Energy lists ipamorelin in its CJC-1295/Ipamorelin card, next to sermorelin and DSIP.
• Muscle & Performance lists it with CJC-1295 and IGF-1 LR3.

For the GHRH-door alternatives, see the sermorelin and CJC-1295 guides. The CJC-1295 plus ipamorelin pairing is covered in CJC-1295 vs Ipamorelin.

Frequently Asked Questions

What does ipamorelin do?

Ipamorelin binds the ghrelin receptor in the pituitary and triggers a short pulse of the body’s own growth hormone. In humans, that’s been measured after single doses. Effects on muscle, fat or health haven’t been shown.

What are the downsides of ipamorelin?

It has no proven benefit, unknown long-term safety, and a place on the FDA’s compounding safety-risk list. Expected risks include water retention, higher blood sugar and hunger. Research vials also carry quality risks.

Is ipamorelin safe?

Its safety hasn’t been established. Short hospital use in one trial was well tolerated, but the FDA has noted serious adverse events with intravenous use, and there’s no long-term data.

Why is ipamorelin banned?

WADA bans it because it raises growth hormone, which can enhance performance. The FDA placed it in Category 2 over immune-reaction risks and serious adverse events seen with intravenous use.

Is ipamorelin legal?

It isn’t FDA-approved, and it’s sold only as a research chemical labeled not for human consumption. It isn’t on the list of substances pharmacies may use for compounding.

Has ipamorelin been tested in humans?

Yes, in a small way: a 1999 study in healthy men and Phase 2 trials in bowel-surgery patients. The published trial didn’t show a clear benefit, and the larger one never posted results.

Does ipamorelin burn belly fat?

There’s no human evidence that it does. In the one mouse study that measured body fat directly, ipamorelin increased fat and food intake, likely because it acts on the hunger-hormone receptor.

Does ipamorelin mess with testosterone?

There’s no evidence it does. In pig studies, ipamorelin didn’t change LH or FSH, the pituitary hormones that drive testosterone production. No human study has measured testosterone with ipamorelin.

Is ipamorelin HGH?

No. Ipamorelin is a small peptide that prompts your pituitary to release its own growth hormone. HGH is the 191-amino-acid hormone itself. They’re related, and both are banned in sport.

What’s the difference between ipamorelin and sermorelin?

Ipamorelin acts on the ghrelin receptor; sermorelin is a copy of the first part of GHRH and acts on the GHRH receptor. See our sermorelin vs ipamorelin comparison.

How much ipamorelin should be used?

There’s no research-based dosing guidance for non-approved use, and we don’t publish dosing. See our Medical Disclaimer.

Disclaimer: Ipamorelin is sold for research use only and isn’t approved for human use. This guide is educational and doesn’t give medical advice. Read our Medical Disclaimer and Editorial Policy to see how we source and review every claim.